Quarterly report · Q3
4886.TEDINET S100SSGE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥48.8bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥60.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥47.3bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥5.5bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥5.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥5.6bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥8.5bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.4bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥94.9bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥87.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥90.8bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.5bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥32.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥60.4bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥54.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥54.1bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥17.5bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥228.13 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.19 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.08 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.19 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.97 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 63.7% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.6% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-12-31 | ¥166m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-12-31 | ¥124m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-12-31 | −¥103m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥41m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥41m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥903m |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥5.1bn |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥5.1bn |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥186m |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥43.6bn |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥43.6bn |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥48.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥48.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥41m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥6.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥196m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥155m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | −¥26m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥41m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥41m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥767m |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E35791-000Animal Health Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥417m |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥41.9bn |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥41.9bn |
| jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥5.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥47.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥47.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥41m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥5.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 328
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)単元株式数100株 | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | Original text (Japanese)同上 | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)あすか製薬ホールディングス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都港区芝浦２丁目５－１ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding guarantee obligations (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentQuarterInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |